Received: 02 November 2021; Published on-line: 21 December 2021
Ultrastructural features of epiretinal membranes after intravitreal injection of various doses of aflibercept in patients with proliferative diabetic retinopathy
Vira S. Ponomarchuk, N.I. Molchaniuk, M. M. Umanets
SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine)
TO CITE THIS ARTICLE: Ponomarchuk Vira S, Molchaniuk NI, Umanets MM. Ultrastructural features of epiretinal membranes after intravitreal injection of various doses of aflibercept in patients with proliferative diabetic retinopathy. J.ophthalmol.(Ukraine). 2021;6:25-30. http://doi.org/10.31288/oftalmolzh202162530
Background: Proliferative diabetic retinopathy (PDR) can cause a loss of vision due to complications like vitreous hemorrhage and tractional retinal detachment, which require vitrectomy. The source of bleeding is usually in pathologic new blood vessels in the fibrovascular epiretinal membrane (ERM). Anti-vascular endothelial growth factor agents are widely used for prevention of intraoperative and postoperative hemorrhagic complications in vitrectomy for PDR.
Purpose: To examine ultrastructural features of ERM after intravitreal injection of various doses of aflibercept in patients with PDR.
Material and Methods: Five patients (5 eyes) were included in the study. ERM specimens with neovascular vessels were taken intraoperatively from the five patients for histological microscopy studies. Specimen No. 1 was taken from the ERM (control ERM) of the patient who did not receive preoperative injection of aflibercept. In addition, specimen No. 2 was taken on day 3 after intravitreal injection of 1.0 mg aflibercept; specimen No. 3, on day 5 after intravitreal injection of 1.0 mg aflibercept; specimen No. 4, on day 3 after intravitreal injection of 2.0 mg aflibercept; and specimen No. 5, on day 5 after intravitreal injection of 2.0 mg aflibercept.
Results: We found that aflibercept had a positive effect on obliteration of newly formed vessels and capillaries. There was a decrease in the size of the lumen of ERM microvessels with an increase in the injected dose and time after injection. In addition, endothelial cells in the newly formed vessels and fibroblasts exhibited active protein synthesis metabolism on day 3 after intravitreal injection of 1.0 mg aflibercept or 2.0 mg aflibercept.
Keywords: proliferative diabetic retinopathy, epiretinal membrane, aflibercept
1.Shkvorchenko DO, Levina LV. [Retinotomy and retinectomy in the management of proliferative diabetic retinopathy complicated by anterior proliferative vitreoretinopathy]. In: [Proceedings of the National Russian Conference on Modern Technologies for the Treatment of Vitreoretinal Pathology]. Moscow; 2006. p. 205-10. Russian.
2.Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep. 2008 Apr 30;41(4):278-86.
3.Hendrick AM, Gibson MV, Kulshresthra A. Diabetic Retinopathy. Prim Care. 2015 Sep;42(3):451-64.
4.Sawa H, Ikeda T, Matsumoto Y. Neovascularization from scleral wound as cause of vitreous rebleeding after vitrectomy for proliferative diabetic retinopathy. Jpn J Ophthalmol. Mar – Apr 2000;44(2):154-60.
5.Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. Feb-Mar 2005;25(2):111-8.
6.Aleman I, Castillo Velazquez J, Rush SW. Ziv-aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomised and controlled trial. Br J Ophthalmol. 2019 Dec;103(12):1740-6.
7.Velazquez JC, Aleman I, Rush SW. Bevacizumab before Diabetic Vitrectomy: A Clinical Trial Assessing 3 Dosing Amounts. Ophthalmol Retina. 2018 Oct; 2(10):1010-20.
8.Antoszyk AN, Glassman AR, Beaulieu WT, et al. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2020 Dec 15;324(23):2383-95.
9.Abd Elhamid AH, Mohamed AAEA., Khattab AM. Intravitreal Aflibercept injection with panretinal photocoagulation versus early vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial. BMC Ophthalmol. 2020 Apr 6;20(1):130.
10.Ponomarchuk Vira S, Vit VV, Umanets MM. Morphological and ophthalmoscopic features of epiretinal membranes after intravitreal injection of various doses of aflibercept in patients with proliferative diabetic retinopathy. J Ophthalmol (Ukraine). 2021;5:3-9.
11.Kohno R, Hata Y, Mochisuki Y, et al. Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol. 2010 Aug;150(2):223-229.e1.
12.Dumbrova NE, Korol AR, Nasinnik IO, et al. [Structural changes in the choroid and retina of the rabbit after intravitreal injections of selective and non-selective anti-VEGF agents]. Oftalmol Zh. 2012;3:68-72. Russian.
13.Vidinova C, Vidinov N. [The effect of bevacizumab on the ultrastructure of choroidal neovascular membranes in patients with age-related macular degeneration (AMD)]. Klin Monbl Augenheilkd. 2009 Jun;226(6):491-5.
14.Vidinova C, Vidinov N. [Comparative ultrastructural analysis of the proliferative tissue in PDR patients with or without vitreous haemorrhage: from ultrastructural approach to clinical practice]. Klin Monbl Augenheilkd. 2007 Mar;224(3):185-9.
15.Ponomarchuk Vira S, Velychko LM, Umanets MM. Vitreous VEGF levels among patients with proliferative diabetic retinopathy depending on the general clinical status and ocular status. J Ophthalmol (Ukraine). 2021;4:19-25.
16.Reynolds ES. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol. 1963 Apr;17(1):208-12.
17.Julien S, Heiduschka P, Hofmeister S, Schraermeyer U. Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion. Br J Ophthalmol. 2008 Oct;92(10):1424-8.
18.Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2814-23.
19.Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol. 2007 Jun;143(6):995-1002.
Author Contributions: Vira S. Ponomarchuk: conducting intravitreal injections, data collection and analysis, writing the text; N. I. Molchaniuk: electron microscopic studies; M.M.Umanets: concept and design of the study, surgical interventions, and editing.
Disclosures:The authors declare no conflict of interest.
There are no external sources of funding.